Both bills would eliminate all legal barriers to the manufacture and sale of generic versions of drugs and vaccines. The more ambitious bill is the Medical Innovation Prize Fund Act, which would apply to all prescription drugs. The narrower proposal is the Prize Fund for HIV/AIDS Act, which would only apply to treatments for HIV/AIDS. The Medical Innovation Prize Fund would create a prize fund equal of .55 percent of US GDP, which is more than $80 billion per year at current levels of U.S. GDP. The HIV/AID Prize Fund would be funded at .02 percent of U.S. GDP, which is equal to more than $3 billion per year at current levels of U.S. GDP.Read the rest
The federal government and private health insurance companies would co-fund the prizes, according to formulas set out in the bills. The cost of the prize funds would be more than offset by the savings from the introduction of generic competition for products.
Both bills have some similar features to Senator Sanders' earlier prize fund bills, but there are also a number of changes. Among those changes are the introduction of an open source dividend element to the bills, which would have at least 5 percent of the prize money going to persons or communities that put knowledge, data, materials or technology into the public domain, or provide royalty free and non-discriminatory access to patents and other intellectual property rights.
Killing off bacteria might seem like a good thing. "Your immediate thought is, 'well, that's good, because they're not supposed to be there anyways," said Mercyhurst College microbiologist Steve Mauro, whose team found fluoxetine in low doses in water near Lake Erie's beaches. "But what about all the other bacteria that are supposed to be there and part of that ecosystem?"Prozac Killing E. coli in the Great Lakes (Thanks, Marilyn!)
Treating clean lake water with similar strength doses killed off E. coli and enterococcus bacteria, both of which can cause serious infections in humans.
The fluoxetine found in Lake Erie is at very low levels--about one nanogram per liter of water, Mauro said. "It doesn't appear to be at a level that would be harmful to humans," or invertebrates, for that matter, though Mauro suspects that fluoxetine combined with other chemicals could be having a cumulative effect on the lake's ecosystem.
Imageshack Swaps Spam Pages for Scam Alerts What it costs to host a malware site - Boing Boing Pharmacist-affiliated LegitScript.com going after online ... Service helps Africans spot fake drugs Boing Boing Counterfeit drugs - Boing Boing Read the rest
Now the US manufacturer, Hospira, says that it will stop production entirely after a bid to start making sodium thiopental in Italy stalled when the Rome government said it would only license manufacture if the drug was not used in executions.Lethal injection drug production ends in the US
Hospira said it intended to manufacture sodium thiopental to serve hospitals but "could not prevent the drug from being diverted to departments of corrections for use in capital punishment procedures".
"We cannot take the risk that we will be held liable by the Italian authorities if the product is diverted for use in capital punishment," the company said.
(Image: Lethal Injection Chamber, a Creative Commons Attribution (2.0) image from blatantnews's photostream) Lethal injection hurts - Boing Boing What does stoning a person to death entail? - Boing Boing Edison electrocuted an elephant 105 years ago today - Boing Boing Read the rest
Top 25 Psychiatric Prescriptions for 2009 (Thanks, Gary!) Previously:Why medical research isn't as useful to you as it could be - Boing ... Pharmaceutical company funds documentary about over-eating Read the rest
The suit was brought by the ACLU and the Public Patent Foundation, who argued that US Patent and Trademark Office was wrong to grant patents on genes, as these are not patentable subject matter. The judge agreed, saying that gene patents are patents on a "law of nature" and called the isolation of genes and filing patents on them "a lawyer's trick that circumvents the prohibition on the direct patenting of the DNA in our bodies but which, in practice, reaches the same result."
Which sounds to me like a precedent against all patents that rely on isolated genes. Of course, this isn't over: the pharma/biotech stalwarts interviewed in the linked NYT piece are talking appeal, and I'm sure they'll try to go all the way to the Supreme Court.
I think that the problem here is in the untested idea that imparting exclusive rights to the genome will incentivize more research than allowing anyone to build on discoveries in the genome. It's clear that some exclusive rights provide an incentive so some people to do work. But these exclusive rights also scare off people who have good ideas but are worried about being bankrupted by someone who beat them to the patent. Read the rest